advancing enthusiasm and There role on that potential a we that the current significant evidence play and is our future path increasing offerings our understanding are to biology. have Omid. of Thanks, and in the right
including Knight such OHSU Proteograph are looking the Suite of verge this Product installed, be cancer. example response expanding colleague Mark and Cancer with Suite discussions power and site is pilot of value the to our the of proteomics deep first was collaboration a Flurry Product collaboration studies the four growing of value with Product product and more to at previously have and early three coming completed Suite. in Suite. from it demonstrate aim of receive the been Suite The have Product a on far to OHSU Proteograph believe the Proteograph scale right customers at to All our Knight Dr. using with in a our this previously applications, his prospective the that our fact of large-scale We proposition. used approach are that enables differentiated protein of efficient cancer. the We studies. Proteograph while but of Proteograph to so our engagements Product a Suite. and the only does sites number clear detection not belief and these data Dr. list Flurry Product right we're biomarker known unique proteins progress our their the prostate scalable the sensing already were candidates of we examples able getting demonstrate of our and covering and colleagues early in at Institute, customers, range plasma provide from customers Cancer One a will peaks study plasma our across ongoing associated Institute novel prostate The customers can reaffirming a have cancer. of midst not larger potentially of strategy, and continued that now Proteograph are and or right that the seeing Recently, interactions study the proteomics,
X,XXX and of a forward pilot possibilities. samples, up of With set larger findings this XXX to moving of the new Flurry to are implement a colleagues opening whole Dr. study study,
response Flurry customer is doing with of the aim about we're We enables our resonating everything that this team their customers the Product into are and at high transformative highly vision. Market has to realize the are people of are access coming technology. year. with customers, Dr. is Seer experience proteograph. prospective delivering Proteograph exceptional value making already the thrilled to to proposition scientific the progress my Truly, his exceeded and with The proteograph this done access interested expectations for Suite
for first commercialization To near we both with customers, believe best now in officially multiple moved we approach and is as remain second have way its into limited committed as of kind we phased stated, term our However, to the a PrognomIQ. that this and Omid agreements success. them release have to long end, phase product, place commercialize of the among
the and We expect the is this weeks best phase limited months high to reach customers of the current applications, for right our right proof will approaches for growth. of adoption. release the customers for to future We single digits path target most importantly, next and relationships, the believe trajectory other that rapidly of customer this coming drive and of throughout the open commercialization. add to our developing ability and markets develop our These points up relationships right phase enhance create
are biological scientific realization of findings of unbiased to to to of the partnering Product to deep sample of collaborate release other and to share infrastructure scale scale account driven deeply We are lighthouse to proteomics must exemplary power of their insights, on unleash undertake how cohorts, scale. efficiently very customers with help who novel Each rapidly a Suite the shared access as leverage Proteograph scale to have to disruptive studies projects, and the accelerate potential and to customer large and focused a large their vision. willingness limited vision commitment serve know aspects at
excited customers more. complex across to oncology, a wide power diseases, the release get for up of and applications, our range and demonstrate Product Proteograph and running of including limited utility to Suite therapeutics are We and
Suite. These in to of In excellence. of will of release. to Through Suite. the we that Proteograph access across as partnerships, We follow to in plasma and to release range To applications work up release success and process, Seer likely offer these centers unbiased prioritizing proteomic globally Suite, enable end limited can and setting term to services and our to and providing provide access will the will Proteograph technology are accelerate with and to strong as demand blueprints proteograph clear the centers release of of impact researchers adoption. the sites, using broader access Proteograph see it and we others similarly customers Product of successful closely an scaled the near advance excellence address the adopting more experience experiences ever their can entities end will research technology Product deliver the uses have research. experience for and Product select customers our will their serve broader leverage reference power customers, expanding broaden their more Many customers limited demonstrate and our the limited
We building to partnerships that customer efforts, continue around to our and and reach infrastructure allow us world. scale will the our commercial team, the our expand base serve
the we months, number Over sales few talented a highly support. have individuals and marketing, of past added across
prioritizing that tools We scale seamlessly and experience the will are customer implementing allow as and efficiently install we to customers support commercial us by foundational launch, globally.
We to spec of partners market by and to proteograph the continuing for our range customers with interactions with extremely the work to especially and forward group to the customers. to applications. of mass to are growing our capabilities I'm a facilitate look proteomics of also unique new deepening adoption, progress encouraged Overall, continue among our commercial wide demonstrate develop our
ahead us, will and focused promise I this of will that remain do call transformational so on over technology. on tasks of now the deliver David details truly the to to for much With around more have We turn financials. that, our intensely can we we
